Sunday, May 24th15.0°C
26424
24291

Drugmaker Pfizer's 4Q net plunges on charges, sales decline, but it beats analyst expectations

Drugmaker Pfizer's fourth-quarter profit plunged 59 per cent because of discontinued operations, restructuring and other charges, and generic competition continuing to bleed sales of former blockbuster medicines.

Despite those pressures and unfavourable currency exchange rates reducing revenue by 3 per cent, Pfizer easily topped Wall Street's expectations.

New York-based Pfizer's stock rose 85 cents, or 2.9 per cent, to $30.51 in afternoon trading.

The world's second-biggest drugmaker said Tuesday that net income fell to $2.57 billion, or 39 cents per share, from $6.32 billion, or 85 cents per share, a year earlier.

Excluding one-time items, Pfizer said income would have been 56 cents per share. Analysts expected 52 cents.

Net income was reduced by the animal health business spinoff last year and the sale of Pfizer's nutrition business in late 2012.

Revenue totalled $13.56 billion, down 2 per cent. Analysts expected $13.36 billion.

Sales of primary care drugs fell 10 per cent to $3.44 billion, mainly on generic competition for Viagra in Europe and for cholesterol fighter Lipitor.

Lipitor, the world's top-selling drug until U.S. generic competition hit two years ago, now faces cheaper copycats in Europe and Australia, too. Those smaller revenues were shifted to the established products unit, where sales edged up 2 per cent to $2.42 billion.

Specialty drug sales dropped 7 per cent to $3.4 billion, on generic competition overseas for two other drugs. Meanwhile, royalties from immune disorder drug Enbrel fell as Pfizer's co-promotion deal winds down.

The bright spot was Pfizer's fledgling cancer drug business, up 26 per cent to $468 million.

But Pfizer's new clot-preventing drug Eliquis, a potential blockbuster that's lagged behind two competitors, brought in only $71 million in the quarter. Pfizer shares that with partner Bristol-Myers Squibb Co.

Pfizer forecast 2014 adjusted profit of $2.20 to $2.30 per share and revenue of about $50.2 billion, despite expecting another $3 billion in revenue losses due to generic competition.

"We start 2014 with a sound strategy and a strong business," CEO Ian Read told analysts on a conference call.

He noted Pfizer will report midstage test results this year for palbociclib for advanced breast cancer, plus some other drugs and vaccines. Analysts are closely watching heavily touted palbociclib, which also is being tested against melanoma, lung and other cancer types.

BernsteinResearch analyst Dr. Timothy Anderson called it a "decent" quarter, noting slightly higher revenue and lower taxes than expected and lower interest, legal and asset-impairment charges. But Pfizer faces more patent expirations on older drugs.

For all of 2013, Pfizer posted net income of $22 billion, up 51 per cent, on revenue of $51.58 billion, down 6 per cent. Pfizer repurchased 1 billion, or 13 per cent, of its shares last year.

___

Follow Linda A. Johnson at http://twitter.com/LindaJ_onPharma

The Canadian Press


Read more Business News

25185


Recent Trending




Today's Market
S&P TSX15200.76-2.85
S&P CDNX703.48+2.97
DJIA18232.02-53.72
Nasdaq5089.36-1.43
S&P 5002126.06-4.76
CDN Dollar0.8137+0.0004
Gold1204.30+1.30
Oil57.45-1.98
Lumber273.80+3.70
Natural Gas2.887-0.064

 
Okanagan Companies
Pacific Safety0.13-0.01
Knighthawk0.010.00
QHR Technologies Inc1.48+0.03
Cantex0.03-0.01
Anavex Life Sciences0.425+0.053
Metalex Ventures0.09+0.01
Russel Metals25.79-0.03
Copper Mountain Mining1.38-0.03
Colorado Resources0.105+0.005
ReliaBrand Inc0.0048-0.0049
Sunrise Resources Ltd0.04+0.01
Mission Ready Services0.175-0.010
Decisive Dividend Corporation2.20+0.60

 



26416

FEATURED Property
2298523845 Lawrence Avenue
4 bedrooms 3 baths
$887,900
more details
image2image2image2
Click here to feature your property
Please wait... loading


Do or do not

Photo: Thinkstock.com“The optimist sees the rose and not its thorns; the pessimist stares at the thorns, oblivious of the rose.” - Kahlil Gibran Good planning is all about managing chan...


Penetrate the smokescreen

Photo: ContributedHas this ever happened to you? You’re in the middle of your second or third “good discussion” with a prospect. Everything’s going great. The prospect seems en...


Squaring the circle

Photo: Thinkstock.comI have been reading about market segmentation and choice. Howard Moskowitz’s research into tomato sauce as retold by Malcom Gladwell on the TED talks (http://www.ted.com/tal...

_



26363




Member of BC Press Council


24875